In the last trading session, 1.23 million Taysha Gene Therapies Inc (NASDAQ:TSHA) shares changed hands as the company’s beta touched 0.93. With the company’s per share price at $1.62 changed hands at -$0.05 or -2.99% during last session, the market valuation stood at $332.01M. TSHA’s last price was a discount, traded about -166.67% off its 52-week high of $4.32. The share price had its 52-week low at $1.19, which suggests the last value was 26.54% up since then. When we look at Taysha Gene Therapies Inc’s average trading volume, we note the 10-day average is 2.12 million shares, with the 3-month average coming to 4.43 million.
Analysts gave the Taysha Gene Therapies Inc (TSHA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.09. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TSHA as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Taysha Gene Therapies Inc’s EPS for the current quarter is expected to be 0.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Instantly TSHA was in red as seen at the end of in last trading. With action -20.98%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -6.36%, with the 5-day performance at -20.98% in the red. However, in the 30-day time frame, Taysha Gene Therapies Inc (NASDAQ:TSHA) is -33.33% down. Looking at the short shares, we see there were 25.88 million shares sold at short interest cover period of 7.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 67.6% from its current market value. According to analyst projections, TSHA’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -208.64% plunge from its current level, while the stock would need to soar -208.64% for it to hit the projected low.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Data shows that the Taysha Gene Therapies Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -33.61% over the past 6 months, a 63.54% in annual growth rate that is considerably higher than the industry average of 28.10%. Year-over-year growth is forecast to reach -46.63% down from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 2.05M. 8 analysts are of the opinion that Taysha Gene Therapies Inc’s revenue for the current quarter will be 1.49M. The company’s revenue for the corresponding quarters a year ago was 3.6M and 3.41M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -43.04%. The estimates for the next quarter sales put growth at -56.25%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -137.69%. The 2025 estimates are for Taysha Gene Therapies Inc earnings to increase by 61.44%.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next quarterly earnings report in February.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.34% of Taysha Gene Therapies Inc shares while 77.17% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 94.50%. There are 77.17% institutions holding the Taysha Gene Therapies Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 9.1722% of the shares, roughly 21.21 million TSHA shares worth $47.51 million.
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 8.1299% or 18.8 million shares worth $42.11 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF . With 5.57 shares estimated at $9.02 million under it, the former controlled 2.72% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.18% of the shares, roughly 4.47 shares worth around $7.23 million.
